LV10182A - Mematinu satuross ciets farmaceitisks zalu veids ar paplasinatu divpakapju izdalisanas profilu un ta razosana - Google Patents

Mematinu satuross ciets farmaceitisks zalu veids ar paplasinatu divpakapju izdalisanas profilu un ta razosana

Info

Publication number: LV10182A
Authority: LV; Latvia
Prior art keywords: solid pharmaceutical; razosana; mematin; drug; expanded
Prior art date: 1992-08-04

Application number

LV931013A

Other languages

English (en)

Other versions

LV10182B (en

Inventor

Eberhard Nuernberg

Erhard Seiller

Stefan Ritsert

Original Assignee

Merz & Co Gmbh & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-04

Filing date

1993-08-04

Publication date

1994-10-20

1993-08-04 Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co

1994-10-20 Publication of LV10182A publication Critical patent/LV10182A/lv

1995-04-20 Publication of LV10182B publication Critical patent/LV10182B/en

Links

239000007787 solid Substances 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
108010076119 Caseins Proteins 0.000 abstract 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
108010033929 calcium caseinate Proteins 0.000 abstract 1
239000005018 casein Substances 0.000 abstract 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 1
235000021240 caseins Nutrition 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
229960004640 memantine Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Botany (AREA)
Zoology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-93-1013A 1992-08-04 1993-08-04 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof LV10182B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4225730A DE4225730C2 (de)	1992-08-04	1992-08-04	Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (2)

Publication Number	Publication Date
LV10182A true LV10182A (lv)	1994-10-20
LV10182B LV10182B (en)	1995-04-20

Family

ID=6464804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-1013A LV10182B (en)	1992-08-04	1993-08-04	Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof

Country Status (17)

Country	Link
US (1)	US5382601A (lv)
EP (1)	EP0582186B1 (lv)
JP (1)	JP3560244B2 (lv)
CN (1)	CN1086708A (lv)
AT (1)	ATE176866T1 (lv)
AU (1)	AU669731B2 (lv)
CA (1)	CA2141691C (lv)
DE (2)	DE4225730C2 (lv)
DK (1)	DK0582186T3 (lv)
ES (1)	ES2128369T3 (lv)
GR (1)	GR3030227T3 (lv)
IL (1)	IL106580A (lv)
LT (1)	LT3201B (lv)
LV (1)	LV10182B (lv)
MX (1)	MX9304675A (lv)
WO (1)	WO1994003158A1 (lv)
ZA (1)	ZA935614B (lv)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5817336A (en) *	1993-04-02	1998-10-06	Orion-Yhtyma Oy	Composition containing selegiline
AUPN605795A0 (en) *	1995-10-19	1995-11-09	F.H. Faulding & Co. Limited	Analgesic pharmaceutical composition
US6139872A (en) *	1996-08-14	2000-10-31	Henkel Corporation	Method of producing a vitamin product
US5866585A (en) *	1997-05-22	1999-02-02	Synchroneuron, Llc	Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) *	1997-05-22	2000-05-02	Synchroneuron, Llc	Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
AU3860797A (en) *	1997-07-16	1999-02-10	Antrin Research Limited	Pharmaceutical formulations for oral administration
US5840334A (en) *	1997-08-20	1998-11-24	Fuisz Technologies Ltd.	Self-binding shearform compositions
US5980941A (en) *	1997-08-20	1999-11-09	Fuisz Technologies Ltd.	Self-binding shearform compositions
US5952389A (en) *	1998-01-13	1999-09-14	Synchroneuron	Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en)	1998-01-13	2001-09-25	Synchroneuron, Llc	Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) *	1998-03-05	1999-09-09	Basf Ag	Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) *	1998-03-31	1999-10-07	Asta Medica Ag	Brauseformulierungen
US6444702B1 (en)	2000-02-22	2002-09-03	Neuromolecular, Inc.	Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) *	2001-12-07	2004-06-24	Lipton Stuart A.	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (en) *	2000-12-07	2008-03-12	Neuromolecular Inc.	Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
WO2005072705A1 (en) *	2004-01-29	2005-08-11	Neuromolecular, Inc.	Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
CA2556214A1 (en) *	2004-02-13	2005-09-01	Neuromolecular, Inc.	Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
CA2556216A1 (en) *	2004-02-13	2005-09-01	Neuromolecular, Inc.	Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
KR100901927B1 (ko) *	2004-06-17	2009-06-10	메르츠 파마 게엠베하 운트 코. 카가아	메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
AU2005265031A1 (en) *	2004-06-17	2006-01-26	Forest Laboratories, Inc.	Modified release formulation of memantine
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja)	2004-06-17	2012-09-12	メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン	メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
JP2008520736A (ja) *	2004-11-23	2008-06-19	アマダスファーマシューティカルズインコーポレイテッド	持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en)	2004-11-24	2013-08-07	Neuromolecular Pharmaceuticals, Inc	Composition and method for treating neurological disease
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
NZ555693A (en) *	2004-12-27	2010-10-29	Eisai R&D Man Co Ltd	Matrix type sustained-release preparation containing donepezil
US20060160852A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Composition containing anti-dementia drug
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CA2604052C (en)	2005-04-06	2014-07-08	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of cns-related conditions
JP5597343B2 (ja) *	2005-04-28	2014-10-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬を含有する組成物
US20060270742A1 (en) *	2005-05-02	2006-11-30	Jane Staunton	Compositions and methods for the treatment of neurodegenerative diseases
WO2006138227A1 (en) *	2005-06-16	2006-12-28	Forest Laboratories, Inc.	Modified and immediate release memantine bead formulation
US7968351B2 (en) *	2005-12-23	2011-06-28	Alk-Abello A/S	Method for dissolution testing of pharmaceutical products
EP2040676A2 (en) *	2006-07-06	2009-04-01	Forest Laboratories, Inc.	Orally dissolving formulations of memantine
US20080069961A1 (en) *	2006-09-14	2008-03-20	Halliburton Energy Services, Inc.	Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) *	2006-11-30	2007-01-10	Pliva Istrazivanje I Razvoj D	Pharmaceutical composition of memantine
US20080182908A1 (en) *	2007-01-25	2008-07-31	Vinita Umashankar Vyas	Pharmaceutical compositions comprising memantine
EP2211836A2 (en)	2007-10-10	2010-08-04	Rubicon Research Private Limited	Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009151498A2 (en) *	2008-03-28	2009-12-17	Forest Laboratories Holdings Limited	Memantine formulations
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
AU2010325960C1 (en)	2009-12-02	2015-08-06	Adamas Pharma, Llc	Amantadine compositions and methods of use
EP2363119A1 (fr) *	2010-03-05	2011-09-07	Centre Hospitalier Universitaire d'Angers	Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
WO2012101653A2 (en)	2011-01-25	2012-08-02	Cadila Healthcare Limited	Modified release pharmaceutical compositions memantine
EP2675435A1 (en)	2011-02-17	2013-12-25	Lupin Limited	Sustained release composition of memantine
TR201104108A2 (tr)	2011-04-27	2011-08-22	Ali̇ Rai̇f İlaç Sanayi̇ A.Ş.	Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) *	2011-10-11	2013-11-15	Univ Clermont Auvergne	Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) *	2012-04-12	2013-10-17	Cerecor, Inc.	Compositions and methods for treating cough
ES2623176T3 (es)	2012-08-16	2017-07-10	Teva Pharmaceutical Industries Ltd.	Composición farmacéutica de memantina
CN105121559A (zh) *	2013-02-08	2015-12-02	巴斯夫欧洲公司	通过反应喷雾干燥的无机/有机复合材料的制备
WO2014204933A1 (en)	2013-06-17	2014-12-24	Adamas Pharmaceuticals, Inc.	Amantadine compositions and methods of use
JP2020531543A (ja)	2017-08-24	2020-11-05	アダマスファーマエルエルシーＡｄａｍａｓＰｈａｒｍａＬＬＣ	アマンタジン組成物、その調製、および使用方法
US20190247331A1 (en)	2018-02-15	2019-08-15	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213394B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213393B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság	Composition and method for treating neurological disease
US11602507B2 (en)	2019-05-27	2023-03-14	Trikona Pharmaceuticals Pvt. Ltd	Extended release oral composition of memantine or its salt and its process for the preparation
CU24720B1 (es)	2020-11-24	2024-10-09	Centro De Neurociencias De Cuba	Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB715874A (en) *	1952-10-03	1954-09-22	Horlicks Ltd	A tablet for use in treating peptic ulcers
GB840091A (en) *	1955-09-08	1960-07-06	Upjohn Co	Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) *	1968-10-09	1971-07-20	Richardson Merrell Inc	Long-lasting troche
ES413944A1 (es) *	1972-04-20	1976-06-01	Merz & Co	Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4076846A (en) *	1974-11-22	1978-02-28	Sumitomo Bakelite Company Limited	Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) *	1975-03-31	1978-11-28	William H. Rorer, Inc.	Medicinal simethicone containing composition and its method of production
US4419369A (en) *	1980-09-22	1983-12-06	Baylor College Of Medicine	Protein mineral dietary module
US4346112A (en) *	1981-06-29	1982-08-24	University Patents Inc.	Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) *	1982-12-02	1984-06-12	Takada Seiyaku Kk	新規なニフエジピン固形製剤
US4913906B1 (en) *	1985-02-28	2000-06-06	Yissum Res Dev Co	Controlled release dosage form of valproic acid
AU593821B2 (en) *	1985-08-06	1990-02-22	Excel Technologies International Corporation	Treating agent for liquid media
US4897380A (en) *	1985-08-30	1990-01-30	Pollack Robert L	Method and composition for relieving dietary-related disorders
US4853377A (en) *	1985-10-15	1989-08-01	Pollack Robert L	Method and composition for increasing production of serotonin
DK179687D0 (da) *	1987-04-08	1987-04-08	Farma Food As	Praeparat
US4792452A (en) *	1987-07-28	1988-12-20	E. R. Squibb & Sons, Inc.	Controlled release formulation
US4925677A (en) *	1988-08-31	1990-05-15	Theratech, Inc.	Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
EP0392059B1 (de) *	1989-04-14	1993-09-15	Merz & Co. GmbH & Co.	Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
EP0550436A1 (en) *	1989-11-06	1993-07-14	Alkermes Controlled Therapeutics, Inc.	Protein microspheres and methods of using them
GB9004950D0 (en) *	1990-03-06	1990-05-02	Kelco Int Ltd	Controlled release formulation
WO1991017745A1 (en) *	1990-05-23	1991-11-28	Southwest Research Institute	Filament system for delivering a medicament and method
FR2664499B1 (fr) *	1990-07-16	1994-11-04	Jacques Dubois	Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

1992
- 1992-08-04 DE DE4225730A patent/DE4225730C2/de not_active Expired - Lifetime
1993
- 1993-07-23 US US08/096,952 patent/US5382601A/en not_active Expired - Lifetime
- 1993-07-28 ES ES93112018T patent/ES2128369T3/es not_active Expired - Lifetime
- 1993-07-28 DK DK93112018T patent/DK0582186T3/da active
- 1993-07-28 AT AT93112018T patent/ATE176866T1/de active
- 1993-07-28 DE DE59309388T patent/DE59309388D1/de not_active Expired - Lifetime
- 1993-07-28 EP EP93112018A patent/EP0582186B1/de not_active Expired - Lifetime
- 1993-08-03 IL IL106580A patent/IL106580A/en not_active IP Right Cessation
- 1993-08-03 MX MX9304675A patent/MX9304675A/es unknown
- 1993-08-03 ZA ZA935614A patent/ZA935614B/xx unknown
- 1993-08-04 CA CA002141691A patent/CA2141691C/en not_active Expired - Lifetime
- 1993-08-04 JP JP50501594A patent/JP3560244B2/ja not_active Expired - Fee Related
- 1993-08-04 LT LTIP839A patent/LT3201B/lt not_active IP Right Cessation
- 1993-08-04 AU AU47069/93A patent/AU669731B2/en not_active Expired
- 1993-08-04 LV LVP-93-1013A patent/LV10182B/en unknown
- 1993-08-04 WO PCT/EP1993/002074 patent/WO1994003158A1/en active Application Filing
- 1993-08-04 CN CN93116211A patent/CN1086708A/zh active Pending
1999
- 1999-05-14 GR GR990401314T patent/GR3030227T3/el unknown

Also Published As

Publication number	Publication date
IL106580A0 (en)	1993-12-08
LT3201B (en)	1995-03-27
IL106580A (en)	1998-02-08
JP3560244B2 (ja)	2004-09-02
ES2128369T3 (es)	1999-05-16
MX9304675A (es)	1994-03-31
WO1994003158A1 (en)	1994-02-17
LV10182B (en)	1995-04-20
GR3030227T3 (en)	1999-08-31
ZA935614B (en)	1995-02-03
EP0582186A1 (de)	1994-02-09
AU4706993A (en)	1994-03-03
CA2141691A1 (en)	1994-02-17
AU669731B2 (en)	1996-06-20
CA2141691C (en)	2002-04-09
EP0582186B1 (de)	1999-02-24
ATE176866T1 (de)	1999-03-15
DE4225730A1 (de)	1994-02-10
US5382601A (en)	1995-01-17
LTIP839A (lt)	1994-08-25
JPH07509479A (ja)	1995-10-19
DK0582186T3 (da)	1999-09-27
DE59309388D1 (de)	1999-04-01
DE4225730C2 (de)	2003-04-30
CN1086708A (zh)	1994-05-18

Publication	Publication Date	Title
LV10182A (lv)	1994-10-20	Mematinu satuross ciets farmaceitisks zalu veids ar paplasinatu divpakapju izdalisanas profilu un ta razosana
WO1997012583A3 (en)	1997-06-05	Stable compositions containing n-propargyl-1-aminoindan
BR0207005A (pt)	2004-02-17	Sistema de distribuição granular, processo para prepará-lo, uso do mesmo, produto ou composição flavorizado(a), e, produto ou composição perfumado(a)
UA26455C2 (uk)	1999-08-30	Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
MY126625A (en)	2006-10-31	Compositions containing diphosphonic acids
MY127797A (en)	2006-12-29	3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
ATE158504T1 (de)	1997-10-15	Brausemischungen enthaltend ibuprofen und verfahren
DK0711151T3 (da)	2000-08-14	Partikler med modificerede fysisk-kemiske egenskaber, deres fremstilling og anvendelser
WO2004050058A3 (en)	2004-09-30	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CA2171303A1 (en)	1995-03-16	Active principles and gas containing microparticles
CA2106172A1 (en)	1994-03-15	Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
FI945912A0 (fi)	1994-12-15	Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
HUP0103454A2 (hu)	2002-01-28	Entacapont vagy nitecapont és keresztkötésű cellulózszármazékot tartalmazó gyógyászati készítmény
ATE79538T1 (de)	1992-09-15	Dispergierbare zubereitung.
DE69622739D1 (de)	2002-09-05	Pharmazeutische zubereitung mit schneller freisetzung
CA2437785A1 (en)	2002-10-10	Hiv inhibiting pyrazinone derivatives
CA2175470A1 (en)	1995-06-01	Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide
GEP20043377B (en)	2004-04-13	Pharmaceutical Complex
CA2001568A1 (en)	1991-03-22	Medicament for treating toxoplasmosis
TH59782A3 (th)	2003-12-04	สารผสมของกาแลนแทมีนชนิดปลดปล่อยที่มีการควบคุม
RU93049678A (ru)	1997-03-10	Устойчивый водорастворимый ветеринарный препарат и способ его получения
GT198800030A (es)	1989-09-28	Un producto para la preparacion de un azol.